NASDAQ:MDGL Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis $214.83 +6.42 (+3.08%) (As of 10/7/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Madrigal Pharmaceuticals Stock (NASDAQ:MDGL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MDGL alerts:Sign Up Key Stats Today's Range$206.73▼$217.7050-Day Range$206.58▼$284.6652-Week Range$119.76▼$299.98Volume464,655 shsAverage Volume431,591 shsMarket Capitalization$4.66 billionP/E RatioN/ADividend YieldN/APrice Target$343.83Consensus RatingModerate Buy Company OverviewMadrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.Read More… Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (Ad)Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Madrigal Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks89th Percentile Overall ScoreMDGL MarketRank™: Madrigal Pharmaceuticals scored higher than 89% of companies evaluated by MarketBeat, and ranked 128th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingMadrigal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 10 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageMadrigal Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Madrigal Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($27.67) to ($17.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Madrigal Pharmaceuticals is -9.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Madrigal Pharmaceuticals is -9.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMadrigal Pharmaceuticals has a P/B Ratio of 10.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Madrigal Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.18% of the outstanding shares of Madrigal Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMadrigal Pharmaceuticals has a short interest ratio ("days to cover") of 13.5, which indicates bearish sentiment.Change versus previous monthShort interest in Madrigal Pharmaceuticals has recently decreased by 0.80%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMadrigal Pharmaceuticals does not currently pay a dividend.Dividend GrowthMadrigal Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.92 Percentage of Shares Shorted17.18% of the outstanding shares of Madrigal Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMadrigal Pharmaceuticals has a short interest ratio ("days to cover") of 13.5, which indicates bearish sentiment.Change versus previous monthShort interest in Madrigal Pharmaceuticals has recently decreased by 0.80%, indicating that investor sentiment is improving. News and Social Media3.2 / 5News Sentiment0.80 News SentimentMadrigal Pharmaceuticals has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Madrigal Pharmaceuticals this week, compared to 7 articles on an average week.Search InterestOnly 3 people have searched for MDGL on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows3 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Madrigal Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,551,490.00 in company stock.Percentage Held by Insiders23.92% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.50% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Madrigal Pharmaceuticals' insider trading history. Receive MDGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MDGL Stock News HeadlinesMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CEO William John Sibold Sells 6,363 SharesSeptember 12, 2024 | insidertrades.comBuy Rating on Madrigal Pharmaceuticals: Rezdiffra’s Rising Prescription Rates and Blockbuster Potential Drive Positive OutlookOctober 7 at 6:21 AM | markets.businessinsider.comU.S. Stock Market Now on Verge of Collapse"Wheels Are Falling Off" The U.S. Stock Market Today, analyst Dan Ferris is back issuing a new warning. He says what's coming next to the U.S. economy could be much worse than anything he's predicted before. And this time, he says, "The trouble is coming straight for Nvidia and the AI market."October 8, 2024 | Stansberry Research (Ad)Is John Paulson’s Best Investment Ever a Buy or SellOctober 5 at 8:00 AM | msn.comIs John Paulson's Best Investment Ever a Buy or SellOctober 4, 2024 | msn.comMadrigal Pharmaceuticals boosts clinical team for NASH researchOctober 3, 2024 | uk.investing.comMadrigal Pharmaceuticals Joins H.C. Wainwright MASH Virtual Investor ConferenceOctober 3, 2024 | msn.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded to Sell by StockNews.comOctober 3, 2024 | americanbankingnews.comSee More Headlines MDGL Stock Analysis - Frequently Asked Questions How have MDGL shares performed this year? Madrigal Pharmaceuticals' stock was trading at $231.38 at the beginning of 2024. Since then, MDGL shares have decreased by 7.2% and is now trading at $214.83. View the best growth stocks for 2024 here. How were Madrigal Pharmaceuticals' earnings last quarter? Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) released its earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($7.10) earnings per share for the quarter, topping analysts' consensus estimates of ($7.55) by $0.45. Madrigal Pharmaceuticals's revenue for the quarter was up 146280.0% on a year-over-year basis. Who are Madrigal Pharmaceuticals' major shareholders? Top institutional investors of Madrigal Pharmaceuticals include Handelsbanken Fonder AB (0.15%) and SG Americas Securities LLC (0.01%). Insiders that own company stock include Bros Advisors Lp Baker, Rebecca Taub, Fred B Craves, Paul A Friedman, William John Sibold, Brian Joseph Lynch, Richard S Levy, Robert E Waltermire, James M Daly and Remy Sukhija. View institutional ownership trends. How do I buy shares of Madrigal Pharmaceuticals? Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Madrigal Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Ayala Pharmaceuticals (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN) and CRISPR Therapeutics (CRSP). Company Calendar Last Earnings8/07/2024Today10/07/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:MDGL CUSIP87162T20 CIK1157601 Webwww.madrigalpharma.com Phone(267) 824-2827Fax781-274-8228Employees90Year Founded2011Price Target and Rating Average Stock Price Target$343.83 High Stock Price Target$410.00 Low Stock Price Target$150.00 Potential Upside/Downside+60.0%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($23.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-373,630,000.00 Net MarginsN/A Pretax Margin-3,487.13% Return on Equity-95.61% Return on Assets-66.71% Debt Debt-to-Equity Ratio0.14 Current Ratio8.72 Quick Ratio8.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$20.53 per share Price / Book10.46Miscellaneous Outstanding Shares21,710,000Free Float16,214,000Market Cap$4.66 billion OptionableOptionable Beta-0.44 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (NASDAQ:MDGL) was last updated on 10/8/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | Sponsored25-Yr Wall St Legend: Get Out of Cash before Nov 6Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.